STAY UPDATED: Sign-up for the Kitman Labs monthly round-up of news. SUBSCRIBE NOW

CONTACT US
BLOG

Use Case: Return to Play with Confidence Using VALD Performance Data

Effective return to play starts with one connected view of rehab progress and readiness—structured, collaborative, and trusted.

SHARE

Share via email

Medical teams must balance an athlete’s well-being with competitive pressures every day. However, when testing results, rehab notes, and training exposure are stored in different locations, decisions slow down and uncertainty increases.

The Performance Medicine Solution in iP: Intelligence Platform unifies this information, delivering a structured, informed return to play strategy. With integrations like VALD Performance feeding objective baselines directly into iP, clinicians can act with clarity—not guesswork.

The Challenge

Return to play decisions are high stakes—but data is often fragmented.

Without centralized information or dynamic comparisons, it’s hard to:

  • Validate recovery against baseline values in seconds
  • Track percentage changes across weeks, not just single sessions
  • Align clinical recovery with training load and exposure
  • Communicate a clear, defensible decision pathway with staff and athletes

What We Hear from Medical Staff

  • “We need more than ‘feels good’—we need objective evidence of readiness.”
  • “Our force plates and strength tests are great, but the data sits outside our medical workflow.”
  • “Comparing back to baseline still takes too long.”
  • “We lose hours exporting, cleaning, and re-entering test results.”

The Solution: iP + Vald Performance Data for Objective Evidence, Unified

With the Performance Medicine Solution in iP, medical staff work within one connected system for athlete health and rehab.

VALD integrations—NordBord, ForceFrame, ForceDecks, DynaMo, SmartSpeed—integrate objective testing data directly into iP, enriching each athlete’s medical profile. Clinicians can validate against baselines, compare their findings to those of teammates, and align their results with training exposure.


Building on iP: Intelligence Platform—VALD Integrations

Validate Readiness with Objective Testing Data

  • Use the isometric, force plate, and speed outputs to confirm recovery against baselines
  • Track asymmetry and neuromuscular control during rehab progression
  • Monitor percentage changes across time windows to spot regression early

Build Return to Play Progressions Linked to Load

  • View VALD testing results alongside session intent and training exposure
  • Pace step-ups with clear, defensible markers tied to objective data
  • Keep medical, performance, and coaching staff aligned on progression criteria

Collect Testing Data Automatically

  • Capture strength, force, jump, agility, and speed benchmarks directly in iP
  • Eliminate manual exports and siloed spreadsheets
  • Maintain a consistent, complete record inside each athlete’s medical profile

See the Return to Play with Vald Testing Data Workflow

Ready to Make Return to Play Evidence-Based?

You don’t need more tests—you need connected evidence. With the Performance Medicine Solution in iP: Intelligence Platform, and VALD integrations feeding objective baselines into iP, return to play becomes an objective, transparent, and faster process.

Already using iP? Message our Performance Experts via the in-platform Message Center.

New to iP? Contact us to see how this workflow fits your environment.

RELATED POSTS

TOPICS

  • EMR Systems
  • Performance Medicine
  • Sports Injury Software
  • Sports Injury Tracking
  • Sports Medicine EMR/EHR
  • Use Case

stay updated

Sign up for the monthly round-up of news from Kitman Labs – new Solutions, client announcements, product enhancements, best practices, customer stories and more. Delivered to your inbox.

STAY UP-TO-DATE!

WITH KITMAN LABS NEWS

Sign up for our monthly round-up of news – new Solutions, client announcements, product enhancements, best practices, customer stories, and more.

Expert advice and industry insights delivered to your inbox

YOU ARE NOW ENTERING THE
AMERICAN
ENGLISH SITE
REDIRECTING TO